Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Inclusion Criteria:

Must have signed an inform consent document
Have histologic or cytologic diagnosis of breast cancer with evidence of unresectable locally recurrent or metastatic disease
Have not received any prior chemotherapy for locally recurrent or metastatic disease
Have not had adjuvant or neoadjuvant taxane therapy within 12 months prior to assignment to study treatment
Age 18 years or older at time of informed consent

Exclusion Criteria:

Have any clinical evidence of central nervous system (CNS) metastases
Have a history of seizure
Have had a major surgical procedure within 4 weeks prior to assignment to study treatment
Have had a minor surgical procedure, placement of an access device, or fine needle aspiration within 7 days prior to assignment to study treatment
Have symptomatic peripheral vascular disease